M. Carreras

Trabectedin plus PLD versus PLD monotherapy in patients with platinum-sensitive relapsed ovarian cancer: a cost-effectiveness analysis in Spain

I. Oyagüez, M. Casado, J. Montalar, 2012 .

Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.

E. Felip, F. de Marinis, M. Taron, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acute kidney injury as a risk factor for mortality in oncological patients receiving check-point inhibitors.

E. Felip, D. Serón, M. Soler, 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Aprataxin Tumor Levels Predict Response of Colorectal Cancer Patients to Irinotecan-based Treatment

Andrew J. Wilson, D. Arango, J. Mariadason, 2010, Clinical Cancer Research.

A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases

J. Baselga, J. Tabernero, P. Komarnitsky, 2014, Clinical Cancer Research.

Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center

F. Bosch, P. Abrisqueta, C. Carpio, 2021, Leukemia & lymphoma.

Pancreatic cancer heterogeneity and response to Mek inhibition

J. Tabernero, J. Arribas, A. Vivancos, 2017, Oncogene.